| abstract |
Compounds of formula (I), and pharmaceutically acceptable salts thereof:n wherein n nL is NH or O; n nX is a moiety capable of hydrogen bonding to the NH group depicted in formula (I); n nR₁ and R₂ are independently selected from hydrogen, halogen, CF₃, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylthio, C 1-7 acyl, C 1-7 acylamino, C 1-6 alkylsulphonylamino, N-(C 1-6 alkylsulphonyl)-N-C 1-4 alkylamino, C 1-6 alkylsulphinyl, carboxy, C 1-6 alkoxycarbonyl, hydroxy, nitro or amino, aminocarbonyl, aminosulphonyl, aminosulphonylamino or N-(aminosulphonyl)-C 1-4 alkylamino optionally N-substituted by one or two groups selected from C 1-6 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl C 1-4 alkyl, phenyl or phenyl C 1-4 alkyl groups or optionally N-disubstituted oy C 4-5 polymethylene; and n Z is a group of formula (a), (b) or (c)n wherein n is 2 or 3; p is l or 2; q is l to 3; r is l to 3: and nR₃ or R₄ is C 1-7 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-2 alkyl or C 2-7 alkenyl-C 1-4 alkyl; having 5-HT M-receptor antagonist activity, a process for their preparation and their use as pharmaceuticals. |